Efficiency of subconjunctival bevacizumab on pterygium
Background: To evaluate the effect and complications of subconjunctival bevacizumab (Avastin ®) on primary and recurrent pterygium. Methods: This prospective study included sixteen patients with pterygium, who received subconjunctival injection of bevacizumab (1.25 mg/0,1 mL). Digital photo...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Slovenian Medical Association
2012-06-01
|
| Series: | Zdravniški Vestnik |
| Online Access: | http://vestnik.szd.si/index.php/ZdravVest/article/view/934 |
| Summary: | Background: To evaluate the effect and complications
of subconjunctival bevacizumab (Avastin
®) on primary and recurrent pterygium.
Methods: This prospective study included sixteen
patients with pterygium, who received
subconjunctival injection of bevacizumab (1.25
mg/0,1 mL). Digital photography was used to
evaluate vascularization of pterygium at 1 week, 1
month and 6 months after injection.
Results: Sixteen patients (9 men and 7 women),
aged between 41 and 74 years, with pterygium
were included in the study. The pterygium was
primary in nine patients and recurrent in seven
patients. A rapid regression of vascularisation of
pterygium was noted one week after treatment
in all patients treated with bevacizumab. The recurrence
was observed in two patients 1 month
and in ten patients 6 months after injection. No
change of visual acuity was noted and no systemic
or ocular adverse events were observed.
Conclusions: Subconjunctival bevacizumab
(Avastin®) was safe and effective in providing a
short-term regression of conjunctival vessels in
the pterygial bed. |
|---|---|
| ISSN: | 1318-0347 1581-0224 |